Tafasitamab-cxix (Monjuvi®, Incyte), in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Join a one-hour webcast to learn more about the usage of Tafasitamab-cxix (Monjuvi®) in treating your patients. For more information, click here.
Posted on 10/06/2020